The Lancet Psychiatry
2025
Carolina Seybert, Nina Schimmers, Lucio Silva et al.
26 citations
Although studies of psychedelic-assisted psychotherapy are accumulating, there is no consensus regarding best practice of the psychotherapeutic component. In this systematic review, we summarised the quality of reporting on psychological interventions in research about psychedelic treatments. The design followed PRISMA guidelines and was preregistered in PROSPERO (CRD42022319221). We searched...
medRxiv
2025
Benjamin R. Lewis, John Hendrick, Kevin Byrne et al.
3 citations
preprint
Abstract Objective This clinical trial sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR for frontline healthcare providers with symptoms of depression and burnout related to the COVID-19 pandemic. Methods This was a randomized controlled trial that enrolled physicians and nurses with frontline clinical work during the COVID-19 pandemic and symptoms of depression and...
Frontiers in Psychiatry
2025
Peter Gasser, Matthias E. Liechti, Friederike Holze
2 citations
A 64-year-old male patient who suffered from traumatic life experiences and neuropathic pain after oncological chemotherapy was treated with medium to high doses of lysergic acid diethylamide (LSD) and high doses and microdoses of methylenedioxymethamphetamine (MDMA). At the beginning of treatment, the patient did not experience any acute subjective effects of LSD at a dose of 200 µg. After...
PLoS One
2025
Sarah Kratina, Carol Strike, Robert Schwartz et al.
1 citation
Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. However, amid renewed scientific and public interest, policy remains restrictive. Existing reviews have made progress in synthesizing the results of studies of psychedelic interventions, especially psilocybin, and particularly with regard to their...
Science
December 20, 2024
Rachel Nuwer
1 citation
A brace of new studies probes benefits and risks for an understudied group.
Journal of the American Academy of Child & Adolescent Psychiatry
December 19, 2024
Jessica K Jeffrey, Marc J. Weintraub, Charles S. Grob
We are writing in response to 2 Letters to the Editor, both of which discussed our commentary, entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution."1 We appreciate the thoughtful responses to our commentary, and we invite further dialogue about this important subject. Both letters emphasized the importance in...
Journal of the American Academy of Child & Adolescent Psychiatry
December 19, 2024
Paul E Croarkin, Isabella Sutherland, Ming-Fen Ho
1 citation
We read with great interest the commentary by Jeffrey et al. entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution."1 We appreciate the efforts of the authors, the scholarship of this commentary, and the advocacy for research initiatives with psychedelic therapeutics such as psilocybin, lysergic acid diethylamide,...
The Oxford Handbook of Psychedelic, Religious, Spiritual, and Mystical Experiences
December 18, 2024
Aaron D. Cherniak, Robin Carhart-Harris, Joel Gruneau Brulin et al.
2 citations
Abstract In this chapter, the authors synthesize the relational developmental perspective of attachment theory with a neuroscientific model: the RElaxed Beliefs Under pSychedelics (REBUS). This synthesis, the authors argue, can serve as an organizing framework for psychedelic science. Attachment theory posits that people develop internal working models (IWMs) of relational experiences with...
Frontiers in Human Neuroscience
December 11, 2024
Scott Shannon, Jamarie Geller
3 citations
We are experiencing a mental health crisis of unprecedented proportions. Over the last two decades this crisis grew from a perfect storm of rising insurance deductibles, escalating social stressors, the COVID-19 pandemic, and a critical workforce deficiency. Perhaps no mental health arena has a greater shortfall of effective treatment options than Post-traumatic Stress Disorder (PTSD) as the...
Current Topics in Behavioral Neurosciences
December 10, 2024
Xiaojue Hu, Ingmar Gorman, Elizabeth M. Nielson
3 citations
Psychedelic Harm Reduction and Integration (PHRI) is a transtheoretical clinical model for working with psychedelic experiences in therapeutic settings. Drawing from harm reduction psychotherapy, psychedelic-assisted therapy, mindfulness-based modalities, and psychodynamic therapy, PHRI offers a framework for clinicians to assist clients in preparing for and integrating psychedelic experiences...